U.S. crossovers help Quell raise $156M as Treg platform heads toward clinic

Quell could be the first to dose a CAR-Treg cell therapy in patients after raising $156 million in a series B round co-led by a slate of U.S. and European investors comprising Jeito Capital, Ridgeback Capital Investments, SV Health Investors and Fidelity.

By year-end, Quell Therapeutics Ltd. expects to start the Phase I/II LIBERATE trial of QEL-001 to prevent organ rejection in liver transplant patients. The first patient would be dosed next year...